Sunovion (United Kingdom)
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Sunovion (United Kingdom), United Kingdom, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
42%
Total
Publications
204
Total Open
Publications
86
Total
Citations
4.6K
Open Access
Percentage
42%
Total
Publications
204
Total Open
Publications
86
Total
Citations
4.6K
Breakdown
Publisher Open
18%
Both
18%
Other Platform Open
6%
Closed
58%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 12%
9
Hybrid 30%
22
No Guarantees 58%
42
Other Platform Open
Domain 90%
44
Public 18%
9
Institution 10%
5
Preprint 4%
2
Other Internet 4%
2
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 45 |
Europe PMC | Domain | 23 |
Semantic Scholar | Public | 8 |
whiterose.ac.uk OAI-PMH Repository | Institution | 3 |
University of Edinburgh - Edinburgh Research Explorer | Institution | 2 |
University College London - UCL Discovery | Institution | 2 |
Research Square | Preprint | 2 |
Radboud University - Radboud Repository | Institution | 2 |
University of Warwick - Warwick Research Archive Portal | Institution | 1 |
University of California - eScholarship University of California | Institution | 1 |